Reaction equation
[Cl:1][C:2]1[N:7]=[N:6][C:5]([N:8]2[CH2:14][CH2:13][CH2:12][N:11]([CH:15]3[CH2:17][CH2:16]3)[CH2:10][CH2:9]2)=[CH:4][CH:3]=1.[C:18]([NH:21][C:22]1[CH:27]=[CH:26][C:25](B(O)O)=[CH:24][CH:23]=1)(=[O:20])[CH3:19]>>[ClH:1].[ClH:1].[CH:15]1([N:11]2[CH2:12][CH2:13][CH2:14][N:8]([C:5]3[N:6]=[N:7][C:2]([C:25]4[CH:26]=[CH:27][C:22]([NH:21][C:18](=[O:20])[CH3:19])=[CH:23][CH:24]=4)=[CH:3][CH:4]=3)[CH2:9][CH2:10]2)[CH2:17][CH2:16]1Participants
3
Procedure
The title compound was prepared by a similar procedure to that described in Example 68, starting from 1-(6-chloro-pyridazin-3-yl)-4-cyclopropyl-perhydro-1,4-diazepine and 4-acetamidophenylboronic acid. 1H NMR (400 MHz, CD3OD) δ 8.47 (d, 1H), 8.08 (d, 1H), 7.94 (d, 2H), 7.85 (d, 2H), 4.33 (broad m, 1H), 4.12 (broad m, 1H), 3.91 (broad m, 4H), 3.62 (broad m, 2H), 2.97 (hept, 1H), 2.55 ((broad m, 1H), 2.43 (broad m, 1H), 2.17 (s, 3H), 1.24 (broad m, 2H), 1.01 (d, 2H).
Sources & evidence
- ORD record
- ord-8a4d099e74044e5986736d68ebe9a625
- Source dataset
- uspto-grants-2014_09
- Patent number
- US08846677B2
Linked notes
Loading…